Jane Street
ESLA icon

Jane Street’s Estrella Immunopharma ESLA Stock Holding History

Jane Street’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,441
Closed -$16.3K – 11933
2025
Q4 		$16.3K Buy
+10,441
New +$19.8K ﹤0.01% 10766
2023
Q4 		– Sell
-20,505
Closed -$192K – 9314
2023
Q3 		$192K Buy
+20,505
New +$207K ﹤0.01% 7652

Other funds holding ESLA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Jane Street's ESLA Position: Q1 2026 in Review

Jane Street sold out of Estrella Immunopharma (ESLA) in Q1 2026, closing a stake of 10,441 shares — an estimated $16.3K sold.

Jane Street first reported a position in ESLA in Q3 2023 and held it in 2 quarters. The position peaked at $192K in Q3 2023. 16 funds tracked by Wall St. Rank hold ESLA as of Q1 2026.

  • Jane Street reported no remaining Estrella Immunopharma position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 10,441 Estrella Immunopharma shares in Q1 2026, an estimated $16.3K.
  • Jane Street first reported a position in Estrella Immunopharma in Q3 2023 and held it in 2 quarters.
  • Jane Street's Estrella Immunopharma position peaked at $192K in Q3 2023.
  • 16 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.